CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Eyepoint Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Eyepoint Pharmaceuticals Inc
480 Pleasant St Ste B300
Phone: (617) 926-5000p:617 926-5000 WATERTOWN, MA  02472-2468  United States Ticker: EYPTEYPT
Business Summary
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
3826 Laboratory analytical instruments
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board Goeran A.Ando 75 1/1/2021 6/26/2018
President, Chief Executive Officer, Director Jay S.Duker 65 7/10/2023 9/26/2016
Executive Vice Chairman of the Board Nancy S.Lurker 66 7/10/2023 9/15/2016
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Icon Bioscience, Inc. 1253 Reamwood Avenue Sunnyvale CA United States

Business Names
Business Name
EyePoint Pharmaceuticals Securities Corporation
EyePoint Pharmaceuticals US, Inc.
EYPT
7 additional Business Names available in full report.

General Information
Number of Employees: 121 (As of 2/29/2024)
Outstanding Shares: 68,096,174 (As of 10/31/2024)
Shareholders: 38
Stock Exchange: NASD
Federal Tax Id: 262774444
Fax Number: (617) 926-5050


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024